Holen Sie sich die Stockscreener-App
32.82
8.00%
2.43
Handel nachbörslich:
33.00
0.18
+0.55%
Schlusskurs vom Vortag:
$30.39
Offen:
$30.91
24-Stunden-Volumen:
1.15M
Relative Volume:
1.50
Marktkapitalisierung:
$2.07B
Einnahmen:
$10.00M
Nettoeinkommen (Verlust:
$-425.15M
KGV:
-3.608
EPS:
-9.0964
Netto-Cashflow:
$-210.48M
1W Leistung:
+6.91%
1M Leistung:
+26.87%
6M Leistung:
+63.53%
1J Leistung:
+109.58%
1-Tages-Spanne:
$30.85
$33.42
1-Wochen-Bereich:
$30.09
$34.05
52-Wochen-Spanne:
$13.50
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
32.82 | 1.92B | 10.00M | -425.15M | -210.48M | -9.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zenas Biopharma Inc (ZBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ZBIO|Zenas Biopharma Inc|Price:30.390|Chg%:-0.600 - TradingKey
TradingKey - TradingKey
Securities Lawsuit Alert: Zenas BioPharma, Inc. (ZBIO) Investors - The National Law Review
Zenas Biopharma Inc (ZBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zenas BioPharma (ZBIO) Dips 2.7% as Resistance Holds: Key Levels to WatchSeasonality Effect - dars.gov.et
ZBIO6353884 Bond Profile — Key Metrics - TradingView
ZBIO6353884 Bond Risk Profile - TradingView
ZBIO6353884 Bond Coupon Profile — Rate & Payments - TradingView
Zenas BioPharma (ZBIO) Gains Nearly 4% as Biotech Momentum BuildsBackspread Trade - dars.gov.et
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says - Moomoo
Zenas BioPharma Grants Inducement Stock Options and RSUs to New Employees - Quiver Quantitative
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
New Zenas hires receive stock awards vesting through 2030 - Stock Titan
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz - The National Law Review
Zenas BioPharma shows promising Phase 3 results for autoimmune drug obexelimab, boosting growth outlook. - Pluang
Zenas BioPharma: Obexelimab Could Build An Autoimmune Franchise (NASDAQ:ZBIO) - Seeking Alpha
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential - Yahoo Finance
Zenas BioPharma (ZBIO) Joins Russell Growth Indexes But Does The Valuation Still Look Pricey - Sahm
ZBIO INVESTOR ALERT: Zenas BioPharma, Inc. Investors with Substa - GuruFocus
The Bull Case For Zenas BioPharma (ZBIO) Could Change Following Its Shift Into Russell Growth Indices - Sahm
If You Invested $1,000 in Zenas BioPharma Inc. (ZBIO) - Stock Titan
ZBIOZenas Biopharma Inc Earnings - Finviz
Zenas BioPharma (ZBIO) Slips 2.75% as Stock Tests Key Support LevelsIV Percentile - dars.gov.et
Zenas Wins Dismissal Of IPO Suit Over R&D Spending Claims - Law360
Zenas BioPharma Shakes IPO Investor’s Cash Burn Rate Lawsuit - Bloomberg Law News
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 2500 Growth Benchmark - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS:ZBIO) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) dropped from Russell 2000 Value Benchmark - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS:ZBIO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Does Zenas BioPharma (ZBIO) Shifting Into Russell Growth Indices Recast Its Core Investment Story? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, In - The National Law Review
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) dropped from Russell 3000E Value Benchmark - marketscreener.com
Join Class Action to Recover Losses from Zenas BioPharma, Inc. (Z - The National Law Review
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class ActionContact Levi & Korsinsky - The National Law Review
Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Investors - The National Law Review
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
ZBIO DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm - TMX Newsfile
Zenas BioPharma, Inc. Actuals & Estimates (NASDAQ:ZBIO) - TradingView
Enterprise value to EBITDA forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Enterprise value to revenue forward of Zenas BioPharma, Inc. – NASDAQ:ZBIO - TradingView
ZBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Price to book forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):